An integrated epigenome and transcriptome analysis identifies PAX2 as a master regulator of drug resistance in high grade pancreatic ductal adenocarcinoma.
Pancreatic ductal adenocarcinoma (PDAC) is notoriously difficult to treat due to its aggressive, ever resilient nature. A major drawback lies in its tumor grade; a phenomenon observed across various carcinomas, where highly differentiated and undifferentiated tumor grades, termed as low and high gra...
Main Authors: | Imlimaong Aier, Rahul Semwal, Aiindrila Dhara, Nirmalya Sen, Pritish Kumar Varadwaj |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2019-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0223554 |
Similar Items
Similar Items
-
Identification of novel dysregulated key genes in Breast cancer through high throughput ChIP-Seq data analysis
by: Utkarsh Raj, et al.
Published: (2017-06-01) -
Unravelling the role of long non-coding RNA - LINC01087 in breast cancer
by: Rashmi Tripathi, et al.
Published: (2020-03-01) -
Integrated transcriptome meta-analysis of pancreatic ductal adenocarcinoma and matched adjacent pancreatic tissues
by: Sevcan Atay
Published: (2020-10-01) -
Syndecans and Pancreatic Ductal Adenocarcinoma
by: Nausika Betriu, et al.
Published: (2021-02-01) -
THE SUBTYPES OF PANCREATIC DUCTAL ADENOCARCINOMAS
by: Apeksha Kakkar, et al.
Published: (2016-12-01)